New Step by Step Map For Mouse
All enrolled sufferers who been given no less than 1 dose of zosuquidar or placebo for the duration of induction were being monitored for the event of adverse functions (439 people, 219 on zosuquidar and 210 on placebo). The most common adverse occasions have been connected to the duration of extended and sizeable myelosuppression as is predicted w